Galindo RJ, Pasquel FJ, Vellanki P, et al. - In general medicine and surgery patients with type 2 diabetes, hospital treatment with degludec-U100 or glargine-U100 is both safe and effective for the management of hyperglycemia.

• In total, 180 general medicine and surgery patients with an admission blood glucose (BG) of 7·8 to 22·2 mmol/L who had been treated with oral agents or insulin prior to hospitalization were randomly allocated (1:1) to a basal bolus regimen using degludec (n = 92) or glargine (n = 88) as the basal and aspart before meals.

• The randomization BG was 12·2 ± 2·9 mmol/L and HbA1c was 84 mmol/mol (9·8 ± 2·0%).

• Between treatment groups, there were no changes in mean daily BG, the proportion of BG in the target range, basal insulin, length of stay, or hospital complications.

• Between degludec and glargine, there were no differences in the proportion of individuals with BG < 3.9 mmol/L or < 3·0 mmol/L.